Ghrelin increases the motivation to eat, but does not alter food palatability.
Homeostatic eating cannot explain overconsumption of food and pathological weight gain. A more likely factor promoting excessive eating is food reward and its representation in the central nervous system (CNS). The anorectic hormones leptin and insulin reduce food reward and inhibit related CNS reward pathways. Conversely, the orexigenic gastrointestinal hormone ghrelin activates both homeostatic and reward-related neurocircuits. The current studies were conducted to identify in rats the effects of intracerebroventricular ghrelin infusions on two distinct aspects of food reward: hedonic valuation (i.e., "liking") and the motivation to self-administer (i.e., "wanting") food. To assess hedonic valuation of liquid food, lick motor patterns were recorded using lickometry. Although ghrelin administration increased energy intake, it did not alter the avidity of licking (initial lick rates or lick-cluster size). Several positive-control conditions ruled out lick-rate ceiling effects. Similarly, when the liquid diet was hedonically devalued with quinine supplementation, ghrelin failed to reverse the quinine-associated reduction of energy intake and avidity of licking. The effects of ghrelin on rats' motivation to eat were assessed using lever pressing to self-administer food in a progressive-ratio paradigm. Ghrelin markedly increased motivation to eat, to levels comparable to or greater than those seen following 24 h of food deprivation. Pretreatment with the dopamine D1 receptor antagonist SCH-23390 eliminated ghrelin-induced increases in lever pressing, without compromising generalized licking motor control, indicating a role for D1 signaling in ghrelin's motivational feeding effects. These results indicate that ghrelin increases the motivation to eat via D1 receptor-dependent mechanisms, without affecting perceived food palatability.
Veterans Administration Puget Sound Health Care System, Office of Research and Development Medical Research Service, Seattle, Washington, USA.
Joost
J
Overduin
Dianne P
DP
Figlewicz
Jennifer
J
Bennett-Jay
Sepideh
S
Kittleson
David E
DE
Cummings
D000818:Animals; D001552:Benzazepines / Q000494:pharmacology; D004435:Eating / Q000187:drug effects* / Q000502:physiology; D005247:Feeding Behavior / Q000187:drug effects* / Q000502:physiology; D005508:Food Deprivation / Q000502:physiology; D054439:Ghrelin / Q000008:administration & dosage / Q000494:pharmacology*; D006706:Homeostasis / Q000187:drug effects / Q000502:physiology; D057967:Infusions, Intraventricular; D008297:Male; D023421:Models, Animal; D009042:Motivation / Q000187:drug effects* / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017447:Receptors, Dopamine D1 / Q000037:antagonists & inhibitors
D001552:Benzazepines; D054439:Ghrelin; D017447:Receptors, Dopamine D1; C534628:SCH 23390